Full Press Release Details
NEWS RELEASE - REGULATED INFORMATION
30 June 2023, 10:00 p.m. CEST
MDxHealth Announces Results of its Extraordinary
General Shareholders' Meeting
IRVINE, CA, and HERSTAL, BELGIUM -
30 June 2023 - MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("mdxhealth"
or the "Company"), a commercial-stage precision diagnostics company, today held an extraordinary general shareholders'
The items on the agenda of the EGM included the
issuance of a new share option plan called the "2023 Share Option Plan" and the renewal of the authorization to the board of
directors to increase the share capital within the framework of the authorized capital. There was no attendance quorum for the EGM, and
the proposed resolutions that were submitted to the meeting were all duly passed.
The minutes of the EGM and documents that were
submitted to the meeting can be accessed via the Company's website.
Mdxhealth is a commercial-stage precision diagnostics
company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based
on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis
of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California,
with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen,
and linkedin.com/company/mdxhealth.
For more information:
LifeSci Advisors (IR & PR)
mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.